Award
NIH Reporter #5R01AR085258-02
Circulating cell free tumor DNA (ctDNA) in patients with immune checkpoint inhibitor associated inflammatory arthritis (ICI-IA): developing a biomarker to assess immunosuppressive drug safety
Recipient
Hospital for Special Surgery
Award Amount
$206,329.00
Ceiling
$206,329.00
Awarded
August 19, 2026
Identifier
5R01AR085258-02
This NIH-funded research project evaluates ctDNA as a biomarker for cancer progression and the safety of immunosuppressive treatment in patients with ICI-associated inflammatory arthritis.
Description
The project measures circulating cell-free tumor DNA in patients with immune checkpoint inhibitor-associated inflammatory arthritis to assess whether it can indicate cancer progression and how it changes after immunosuppressive treatment.